Want to see TSE:ZRO full AI Analyst Report?
ZRO Stock Chart & Stats
C$0.04
-C$0.04(-50.00%)
At close: 4:00 PM EDT
C$0.04
-C$0.04(-50.00%)
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.15
Previous CloseN/A
Volume8.50K
Average Volume (3M)2.93K
Market Cap
C$1.22M
Enterprise ValueC$2.70M
Total Cash (Recent Filing)C$10.38K
Total Debt (Recent Filing)C$973.87K
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding34,768,887
10 Day Avg. Volume5,790
30 Day Avg. Volume2,930
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-0.40
Price to Sales (P/S)3296.23
P/FCF Ratio-8.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth MomentumSharp TTM revenue increase signals durable top-line momentum and improving market traction for products. If sustained, higher revenue can enable scale economies, support improved gross margins over time, and provide operational runway to address structural cost issues.
Asset-light Manufacturing / Licensing ModelA business model that leverages third-party manufacturing and licensing reduces fixed capex and factory overhead, enabling faster scaling and lower break-even. This structural flexibility can preserve cash and allow focus on R&D, sales, and distribution to build durable revenue streams.
Improving Cash Burn TrendYear-over-year improvement in free cash flow reflects tangible progress cutting burn or improving revenue conversion. Continued improvement reduces dependence on external funding, easing refinancing pressure and improving the likelihood of reaching cash break-even within months if trends persist.
Bears Say
Deeply Negative Shareholders' EquitySeverely negative equity is a structural solvency red flag that limits borrowing capacity and forces reliance on dilutive capital raises or distressed financing. This constrains strategic options and heightens refinancing and creditor risk over the medium term.
Negative Gross Profit And Large Net LossesPersistent negative gross profit and multi-year net losses indicate the core unit economics are not covering cost of goods or operating costs. Without meaningful improvements to pricing, costs, or product mix, margins remain structurally impaired and profitability recovery is uncertain.
Persistent Negative Operating And Free Cash FlowOngoing negative operating and free cash flow demonstrate real cash burn rather than accounting-only losses. Continued outflows require external funding, creating dilution/refinancing risk and limiting the company's ability to invest in growth or absorb shocks without fresh capital.
Biosenta Inc News
ZRO FAQ
What was Biosenta Inc’s price range in the past 12 months?
Biosenta Inc lowest stock price was C$0.01 and its highest was C$0.15 in the past 12 months.
What is Biosenta Inc’s market cap?
Biosenta Inc’s market cap is C$1.22M.
When is Biosenta Inc’s upcoming earnings report date?
Biosenta Inc’s upcoming earnings report date is Sep 02, 2026 which is in 28 days.
How were Biosenta Inc’s earnings last quarter?
Biosenta Inc released its earnings results on May 29, 2026. The company reported -C$0.016 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.016.
Is Biosenta Inc overvalued?
According to Wall Street analysts Biosenta Inc’s price is currently Overvalued.
Does Biosenta Inc pay dividends?
Biosenta Inc does not currently pay dividends.
What is Biosenta Inc’s EPS estimate?
Biosenta Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biosenta Inc have?
Biosenta Inc has 34,768,887 shares outstanding.
What happened to Biosenta Inc’s price movement after its last earnings report?
Biosenta Inc reported an EPS of -C$0.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biosenta Inc?
Currently, no hedge funds are holding shares in TSE:ZRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biosenta Inc
Biosenta Inc., a Toronto-based Canadian firm established in 1986, specializes in the development, manufacturing, and sale of antimicrobial chemical compounds for both residential and commercial applications throughout the country. The company is actively working on "true," an innovative, dual-action disinfectant with potent antimicrobial capabilities, engineered to instantaneously eradicate viruses, bacteria, mold, and various germs upon contact. Additionally, Biosenta Inc. intends to produce and distribute "Tri-Filler," an antimicrobial additive designed for bulking and filling purposes.
Technical Analysis
BioNeutra Global
―
Lifeist Wellness
―
Psyched Wellness
―
Happy Supplements Inc.
―
Pure to Pure Beauty Inc.
―